Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mesoblast Limited
  6. News
  7. Summary
    MSB   AU000000MSB8

MESOBLAST LIMITED

(MSB)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mesoblast : Chardan Adjusts Mesoblast's Price Target to $6.50 From $7.50, Maintains Sell Rating

08/31/2021 | 08:33am EST


© MT Newswires 2021
All news about MESOBLAST LIMITED
12/07MESOBLAST : REXLEMESTROCEL-L SHOWS GREATEST TREATMENT BENEFIT ON MAJOR ADVERSE CARDIOVASCU..
PU
12/06Health Care Stocks Inch Higher Pre-Bell Monday
MT
12/06Health Care
MT
12/06Mesoblast's Heart Disease Drug Candidate Shows Most Benefit in Diabetes, Ischemia Patie..
MT
12/05Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Event..
GL
12/05MESOBLAST : Global CardioVascular Clinical Trialists Forum Presentation
PU
12/02MESOBLAST : CHAIRMAN'S ADDRESS TO SHAREHOLDERS 2021 MESOBLAST ANNUAL GENERAL MEETING - For..
PU
11/28MESOBLAST : CEO Presentation to 2021 Annual General Meeting
PU
11/26MESOBLAST : AND OAKTREE CAPITAL ENTER INTO REFINANCING AND EXPANSION OF SENIOR DEBT FACILI..
PU
11/24Mesoblast's Fiscal Q1 Loss Narrows, Revenue Grows
MT
More news
Analyst Recommendations on MESOBLAST LIMITED
More recommendations
Financials
Sales 2022 46,4 M 33,1 M 33,1 M
Net income 2022 -131 M -93,7 M -93,7 M
Net cash 2022 21,7 M 15,5 M 15,5 M
P/E ratio 2022 -6,69x
Yield 2022 -
Capitalization 1 141 M 818 M 815 M
EV / Sales 2022 24,1x
EV / Sales 2023 12,6x
Nbr of Employees 83
Free-Float 85,7%
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 1,76 AUD
Average target price 2,68 AUD
Spread / Average Target 52,0%
EPS Revisions
Managers and Directors
Silviu Itescu Chief Executive Officer, MD & Executive Director
Andrew Chaponnel Chief Financial Officer & Head-Finance
Joseph R. Swedish Independent Non-Executive Chairman
Fred Grossman Chief Medical Officer
Dagmar Rosa-Bjorkeson Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
MESOBLAST LIMITED-21.78%818
MODERNA, INC.171.27%114 904
LONZA GROUP AG30.52%59 816
IQVIA HOLDINGS INC.51.92%51 999
SEAGEN INC.-14.61%27 346
CELLTRION, INC.-42.20%24 169